Recently, Caribou Biosciences announced the termination of development of all its clinical pipelines, large-scale layoffs, and the initiation of a strategic review that includes mergers, acquisitions, and asset sales.
Under California's WARN Act, Caribou will lay off 87 employees, effective December 7. The company had 97 full-time employees as of February 27, 2026, meaning the layoffs will affect approximately 90% of its workforce .
Caribou's co-founders include Jennifer Doudna, a pioneer of CRISPR gene editing technology and the 2020 Nobel Prize laureate in Chemistry; the company was also one of the first to bring CRISPR to clinical application.
From Nobel Prize Labs to Nasdaq
In 2011 , Jennifer Doudna's Berkeley lab had just unveiled the CRISPR-Cas9 gene-editing tool when she and her PhD student, Rachel Haurwitz, co-founded Caribou Biosciences, with venture capital firm Atlas Venture providing $11 million in seed funding. In 2014, Caribou, along with Atlas Venture, spun off the gene-editing company Intellia, with Caribou holding a 21.5% stake at the time of its IPO.
In 2020 , Doudna and Emmanuelle Charpentier won the Nobel Prize in Chemistry for their contributions to CRISPR/Cas9, thus cementing Caribou's reputation as a Nobel Prize-backed company and attracting significant investment. In February 2021, AbbVie and Caribou entered into a $340 million collaboration to develop a universal CAR-T therapy; in March of the same year, the company completed a $115 million Series C funding round; and in July, it went public on Nasdaq at $16 per share, raising approximately $304 million with a valuation of approximately $900 million. To date, Caribou has raised over $800 million in total funding.
Caribou's technology platform is called chRDNA, which the company claims demonstrates higher specificity and efficiency in preclinical studies, enabling precise multiplex editing without compromising genome integrity. The company was betting on the highly competitive allogeneic CAR-T therapy market. Traditional CAR-T requires extracting the patient's own T cells, modifying and expanding them in a laboratory, and then reinfusing them—a time-consuming and expensive process, with efficacy dependent on the quality of the patient's own T cells. Allogeneic CAR-T aims to use cells from healthy individuals to create standardized products that can be used directly by patients when needed, theoretically shortening waiting times, reducing costs, and making cell therapy accessible to more people.
Caribou's current clinical pipeline includes: vispa-cel, which targets CD19 , for relapsed/refractory B-cell non-Hodgkin lymphoma; and CB-011, which targets BCMA , for relapsed/refractory multiple myeloma. Vispa-cel knocks out the PD-1 gene, and the company claims it is the first donor-derived CAR-T to use this editing method. CB-011 uses an immune camouflage approach, knocking out B2M while inserting a B2M-HLA-E fusion protein to reduce the patient's immune system's rejection of allogeneic cells.
In the Phase I CaMMouflage trial of CB-011, among 12 treatment-naïve patients receiving the recommended dose of BCMA, the overall response rate reached 92%, with 83% achieving complete or better remission . vispa-cel has received Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations from the FDA. The company has also communicated with the FDA to finalize the Phase III ANTLER-3 trial protocol, planning to recruit approximately 250 second-line patients who are ineligible for transplantation or autologous CAR-T therapy.
This is the brightest chapter in Caribou's narrative: Nobel Prize-level science, exclusive platform, endorsement from a major pharmaceutical company, a stellar IPO, and impressive clinical data. It possesses almost all the elements a star biotech company should have.
The data itself wasn't the problem, but the capital withdrew first.
However, the turning point in the story was not because the drug was unsafe or its efficacy was less than expected, but because it was difficult to secure funding .
On October 6, Caribou officially announced the discontinuation of development of two clinical-stage allogeneic CAR-T drugs, significant layoffs, and the initiation of a strategic review to explore alternative paths such as mergers and acquisitions or asset sales. The cancelled projects are vispa-cel and CB-011.
The company estimates restructuring-related expenses to be between $15 million and $19 million, including approximately $10 million to $11 million in employee severance pay and health insurance, and an additional $5 million to $8 million for terminating two clinical trials. The board approved the restructuring plan on October 2nd, with most affected employees expected to leave in the fourth quarter of 2026. The WARN file indicates a final layoff of 87 people, effective December 7th, representing 90% of the company's 97 employees.
On the day the news was announced, the company's stock price closed down 4.62% at $1.14, and fell as low as $0.74 in after-hours trading; the following day, the pre-market decline exceeded 40%. In comparison, its stock price peaked above $32 in September 2021, and has now fallen below $1.
Management emphasized that the failure was not due to scientific or clinical data. CEO Rachel Haurwitz lamented on LinkedIn that this was a sad turning point for Caribou. She mentioned that vispa-cel was the first allogeneic product that could rival autologous CAR-T in terms of safety, efficacy, and sustained remission, and that the Phase III trial protocol had been agreed upon with the FDA. The ANTLER Phase I data released in June 2026 showed that, as second-line treatment for large B-cell lymphoma, vispa-cel's median progression-free survival was comparable to Bristol-Myers Squibb's Breyanzi and Gilead's Kite's Yescarta.
Haurwitz stated that making this decision does not mean the team no longer believes in the technology or clinical data, nor does it mean these drugs have no value for patients. The real challenge is that the current funding environment in the allogeneic CAR-T field is too poor, and the company cannot obtain sufficient funds to steadily advance the project.
As of June 30, 2026, the company had $113.8 million in cash, cash equivalents, and marketable securities. However, this amount is far from enough to support the completion of clinical projects, which is the core contradiction of the whole affair.
The current enthusiasm of investors and industry giants is overwhelmingly focused on in vivo CAR-T. In 2025, AbbVie acquired Capstan Therapeutics for $2.1 billion, BMS acquired Orbital Therapeutics for $1.5 billion, Johnson & Johnson locked in Sail Biomedicines with a $785 million upfront payment and $2.58 billion in options, and AstraZeneca acquired EsoBiotec, which owns the lentivirus platform. In contrast, Gilead's Kite terminated its $2.3 billion allogeneic CAR-NK partnership with Shoreline in 2025, instead investing hundreds of millions of dollars in in vivo CAR-T.
The biggest selling point of allogeneic CAR-T is its immediate availability and lack of waiting time. However, autologous CAR-T manufacturers, such as Kite, have already reduced Yescarta's production turnaround time to 14 days and plan to quadruple its production capacity by 2026. With the waiting time for autologous CAR-T shortened to less than two weeks and the accumulation of up to five years of clinical evidence of durable remission, the differentiated advantage of allogeneic off-the-shelf therapies is significantly reduced.
The misalignment of technology and capital
If Caribou were the only company failing, it would just be another typical case in the biotech industry's high attrition rate. But viewed within the broader industry context, its predicament is actually a microcosm of the cooling off of the allogeneic CAR-T field.
Caribou is not the first allogeneic CAR-T company to scale back its business due to financial difficulties. Andrew Schiermeier, CEO of AvenCell Therapeutics, said in an interview in February 2026 that the sector had entered a capital winter, with funds beginning to flow towards autologous CAR-T and in vivo CAR-T.
Many peers are adjusting their strategies. For example, Arsenal Biosciences abandoned its in vitro autologous CAR-T pipeline to focus resources on in vivo CAR-T, laying off 99 employees, nearly 78% of its workforce. TScan Therapeutics also cut some projects and laid off about 75% of its staff, prioritizing in vivo CAR-T for solid tumors. The entire cell therapy industry is shifting from "in vitro cell preparation" to "direct in vivo generation."
Of course, not all capital has abandoned the allogeneic approach. Roche, for example, spent $1.5 billion to acquire Poseida, betting on the future potential of scaling up allogeneic CAR-T. This shows that the clinical value of allogeneic CAR-T itself has not been denied; it's just that, at present, it is no longer a priority for capital investment.
Looking back at Caribou's choice, it took a scientifically correct but also the most expensive route. For allogeneic CAR-T to complete Phase III clinical trials and be put into production, it requires long-term and continuous investment of huge sums of money. However, the capital market is unwilling to continue to pay for this track that has not yet proven its commercial potential.
Back in April 2025, Caribou had already adjusted its strategy, laying off 47 people (approximately 32%), cutting its lupus-related pipeline, and concentrating all resources on its two oncology projects, vispa-cel and CB-011. At that time, the company estimated that the remaining funds could support operations until the second half of 2027. However, the industry outlook did not improve, and a year and a half later, it faced this near-fatal contraction.
Clinically, the technology is progressing smoothly, but investors are unwilling to continue investing. This is a typical example of a mismatch between technology and capital.
Conclusion
Caribou's experience has also made the industry rethink a long-standing question: Can a Nobel Prize-winning scientist start a successful business?
During the 2026 Nobel Prize season, an organization compiled statistics on 20 life science companies founded, co-founded, or led by Nobel laureates, and their fates varied greatly. Some, like Alnylam, achieved quarterly sales in the billions of dollars; others, like Capstan, were acquired by large pharmaceutical companies for $2.1 billion; still others, like Intellia and Scribe, continue to invest in clinical trials; and many others have scaled back, been sold, or exited the market—Jounce has been acquired, and Caribou is seeking a new path.
The examples of Caribou and Jounce illustrate one fact: scientific value and corporate value are never the same thing. Jounce's co-founder, 2018 Nobel laureate James Allison, pioneered immune checkpoint therapy, which revolutionized cancer treatment, but the company was ultimately acquired by Concentra Biosciences in 2023.
The difference between the two is that science only needs to verify whether a principle is valid, while a company has to solve much more complex problems, such as whether the technology can be mass-produced stably, whether the safety window is wide enough, whether the risks can be controlled, whether clinical trials can prove the benefits, whether the product is competitive, and most importantly, whether capital can accompany the company throughout the long R&D cycle.
Therefore, the layoff of nearly 90% of Caribou's employees cannot be simply interpreted as a narrative that even a Nobel laureate company couldn't survive. A more accurate view is that it vividly demonstrates that the path from basic scientific discovery to successful drug launch is not easy and involves enormous challenges. No matter how dazzling the scientific halo, it cannot replace the hurdles of process development, clinical trials, capital planning, and business judgment.

Source: https://news.yaozh.com/archive/49225.html